Ganesh Raghu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1200152/publications.pdf

Version: 2024-02-01

237 papers	47,727 citations	5248 83 h-index	1745 212 g-index
239 all docs	239 docs citations	239 times ranked	19939 citing authors

#	Article	IF	Citations
1	R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life. European Respiratory Journal, 2022, 59, 2100917.	3.1	9
2	A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen. Annals of the American Thoracic Society, 2022, 19, 594-602.	1.5	17
3	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosisâ€“Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 674-684.	2.5	57
4	Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial). American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1084-1092.	2.5	10
5	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	2.5	15
6	Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease. Chest, 2022, 162, 603-613.	0.4	10
7	Soluble ECM promotes organotypic formation in lung alveolar model. Biomaterials, 2022, 283, 121464.	5.7	16
8	Associations of Monocyte Count and Other Immune Cell Types with Interstitial Lung Abnormalities. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 795-805.	2.5	11
9	Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 56-69.	2.5	25
10	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2022, 205, e18-e47.	2.5	780
11	Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society, 2022, 19, 833-844.	1.5	23
12	Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society, 2022, 19, 1030-1039.	1.5	19
13	Transbronchial Lung Cryobiopsy in Patients with Interstitial Lung Disease: A Systematic Review. Annals of the American Thoracic Society, 2022, 19, 1193-1202.	1.5	32
14	Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society, 2022, 19, 1040-1049.	1.5	24
15	Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study. Respiratory Research, 2022, 23, .	1.4	17
16	Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest, 2022, 162, 614-629.	0.4	19
17	A Phase IIb Randomized Clinical Study of an Anti-Î±_vÎ²₆ Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1128-1139.	2.5	29
18	Randomized Phase IIa Clinical Study of an Anti-Î±_vÎ²₆Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1166-1168.	2.5	9

#	Article	IF	Citations
19	Diagnosis of Hypersensitivity Pneumonitis in Adults, 2020 Clinical Practice Guideline: Summary for Clinicians. Annals of the American Thoracic Society, 2021, 18, 559-566.	1.5	10
20	Questionnaires or Serum Immunoglobulin G Testing in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. Annals of the American Thoracic Society, 2021, 18, 130-147.	1.5	12
21	Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 211-220.	2.5	55
22	The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Research, 2021, 7, 00529-2020.	1.1	22
23	Cryobiopsy for Identification of Usual Interstitial Pneumonia and Other Interstitial Lung Disease Features. Further Lessons from COLDICE, a Prospective Multicenter Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1306-1313.	2.5	32
24	Associations of Ï‰-3 Fatty Acids With Interstitial Lung Disease and Lung Imaging Abnormalities Among Adults. American Journal of Epidemiology, 2021, 190, 95-108.	1.6	11
25	Transbronchial Biopsy and Cryobiopsy in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. Annals of the American Thoracic Society, 2021, 18, 148-161.	1.5	13
26	Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with N-acetylcysteine. European Respiratory Journal, 2021, 57, 2003551.	3.1	6
27	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respiratory Medicine,the, 2021, 9, 96-106.	5.2	118
28	Survival predictors of interstitial lung disease in India: Follow-up of Interstitial Lung Disease India registry. Lung India, 2021, 38, 5.	0.3	3
29	Hypersensitivity Pneumonitis and (Idiopathic) Pulmonary Fibrosis Due to Feather Duvets and Pillows. Archivos De Bronconeumologia, 2021, 57, 87-93.	0.4	9
30	Reply to MorÃ¡n-Mendoza and Khalil: Are Ground-Glass Opacities on Chest High-Resolution Computed Tomography a Manifestation of Airway Disease?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 781-782.	2.5	0
31	Associations of D-Dimer with Computed Tomographic Lung Abnormalities, Serum Biomarkers of Lung Injury, and Forced Vital Capacity: MESA Lung Study. Annals of the American Thoracic Society, 2021, 18, 1839-1848.	1.5	3
32	Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis. JAMA - Journal of the American Medical Association, 2021, 325, 1841.	3.8	43
33	Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. Journal of Inflammation, 2021, 18, 17.	1.5	9
34	Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. European Respiratory Review, 2021, 30, 210011.	3.0	104
35	Use of a Genomic Classifier in Patients with Interstitial Lung Disease: A Systematic Review. Annals of the American Thoracic Society, 2021, , .	1.5	10
36	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e3-e23.	2.5	41

#	Article	IF	Citations
37	Lung transplantation for interstitial lung disease. European Respiratory Review, 2021, 30, 210017.	3.0	36
38	Cryptogenic organising pneumonia: current understanding of an enigmatic lung disease. European Respiratory Review, 2021, 30, 210094.	3.0	23
39	The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Current Neuropharmacology, 2021, 19, 1202-1224.	1.4	44
40	Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. European Respiratory Journal, 2021, 57, 2004219.	3.1	2
41	In Reply. Archives of Pathology and Laboratory Medicine, 2021, 145, 1326-1327.	1.2	1
42	Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review. European Respiratory Review, 2021, 30, 210123.	3.0	23
43	Interstitial lung disease before and after COVID-19: a double threat?. European Respiratory Journal, 2021, 58, 2101956.	3.1	26
44	Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine,the, 2020, 8, 25-33.	5.2	165
45	Risk factors for disease progression in idiopathic pulmonary fibrosis. Thorax, 2020, 75, 78-80.	2.7	22
46	Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respiratory Medicine,the, 2020, 8, 171-181.	5.2	253
47	Associations of Serum Adipokines With Subclinical Interstitial Lung Disease Among Community-Dwelling Adults. Chest, 2020, 157, 580-589.	0.4	17
48	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). European Respiratory Review, 2020, 29, 200287.	3.0	82
49	The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. Annals of the American Thoracic Society, 2020, 17, 1620-1628.	1.5	27
50	Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study. ERJ Open Research, 2020, 6, 00152-2020.	1.1	15
51	Bronchoalveolar Lavage Lymphocytes in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1455-1467.	1.5	29
52	Methodologies of COLDICE and Cryo-PID studies: details make the difference. Annals of Translational Medicine, 2020, 8, 781-781.	0.7	1
53	Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e36-e69.	2.5	508
54	Regional distribution of high-attenuation areas on chest computed tomography in the Multi-Ethnic Study of Atherosclerosis. ERJ Open Research, 2020, 6, 00115-2019.	1.1	9

#	Article	IF	Citations
55	COVID-19 interstitial pneumonia: monitoring the clinical course in survivors. Lancet Respiratory Medicine,the, 2020, 8, 839-842.	5.2	95
56	Recurrent Pulmonary Fibrosis in a Lung Allograft Secondary to De Novo Antisynthetase Syndrome. Annals of the American Thoracic Society, 2020, 17, 901-904.	1.5	5
57	Management of Patients with Interstitial Lung Disease in the Midst of the COVID-19 Pandemic. Respiration, 2020, 99, 625-627.	1.2	14
58	Fibrotic interstitial lung diseases and air pollution: a systematic literature review. European Respiratory Review, 2020, 29, 200093.	3.0	33
59	A Molecular Classifier That Identifies Usual Interstitial Pneumonia in Transbronchial Biopsy Specimens of Patients With Interstitial Lung Disease. Chest, 2020, 157, 1391-1392.	0.4	1
60	Telemedicine â€" maintaining quality during times of transition. Nature Reviews Disease Primers, 2020, 6, 45.	18.1	53
61	Reference values for high attenuation areas on chest CT in a healthy, neverâ€smoker, multiâ€ethnic sample: The MESA study. Respirology, 2020, 25, 855-862.	1.3	13
62	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine, 2020, 382, 779-781.	13.9	8
63	A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk ofÂPulmonary Hypertension Associated With Pulmonary Fibrosis. Chest, 2020, 158, 637-645.	0.4	62
64	Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2020, 20, 3.	0.8	61
65	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.4	33
66	Antinuclear antibodies and subclinical interstitial lung disease in community-dwelling adults: the MESA study. European Respiratory Journal, 2020, 55, 1902262.	3.1	1
67	Prognostic impact of typical and probable usual interstitial pneumonia pattern in idiopathic pulmonary fibrosis: is the debate about biopsy a Star Wars saga?. European Respiratory Journal, 2020, 55, 2000590.	3.1	2
68	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India, 2020, 37, 359-378.	0.3	2
69	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India, 2020, 37, 359.	0.3	9
70	Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 12-21.	2.5	102
71	Circulating adhesion molecules and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. European Respiratory Journal, 2019, 54, 1900295.	3.1	16
72	Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respiratory Medicine,the, 2019, 7, 657-664.	5.2	73

#	Article	IF	Citations
73	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	2.5	60
74	Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. Scientific Reports, 2019, 9, 14802.	1.6	12
75	The 2018 Diagnosis of Idiopathic Pulmonary Fibrosis Guidelines: Surgical Lung Biopsy for Radiological Pattern of Probable Usual Interstitial Pneumonia Is Not Mandatory. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1089-1092.	2.5	45
76	Idiopathic pulmonary fibrosis: shifting the concept to irreversible pulmonary fibrosis of many entities. Lancet Respiratory Medicine,the, 2019, 7, 926-929.	5.2	10
77	Hypersensitivity Pneumonitis: Current Concepts of Pathogenesis and Potential Targets for Treatment. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 301-308.	2.5	94
78	Nintedanib for Systemic Sclerosisâ€“Associated Interstitial Lung Disease. New England Journal of Medicine, 2019, 380, 2518-2528.	13.9	1,025
79	Cryobiopsy for Interstitial Lung Disease: The Heat Is On. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1183-1184.	2.5	12
80	Sarcoidosis and idiopathic pulmonary fibrosis: The same tale or a tale of two diseases in one. Respiratory Medicine, 2019, 160, 105668.	1.3	4
81	Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respiratory Medicine,the, 2019, 7, 487-496.	5.2	119
82	Idiopathic Pulmonary Fibrosis Guideline Recommendations. Need for Adherence to Institute of Medicine Methodology?. Annals of the American Thoracic Society, 2019, 16, 681-686.	1.5	15
83	Surgical lung biopsy for interstitial lung disease: when considered necessary, should these be done in larger and experienced centres only?. European Respiratory Journal, 2019, 53, 1900023.	3.1	9
84	Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. European Respiratory Review, 2019, 28, 190022.	3.0	89
85	Accuracy of Digital Tomosynthesis of the Chest in Detection of Interstitial Lung Disease Comparison With Digital Chest Radiography. Journal of Computer Assisted Tomography, 2019, 43, 109-114.	0.5	2
86	Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 336-347.	2.5	99
87	Reply to Moodley and to Ravaglia et al.. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 667-669.	2.5	0
88	Nicotine Modulates Growth Factors and MicroRNA to Promote Inflammatory and Fibrotic Processes. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 169-178.	1.3	23
89	Lung function outcomes in the INPULSISÂ® trials of nintedanib in idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 146, 42-48.	1.3	34
90	Hypersensitivity pneumonitis and its correlation with ambient air pollutionÂinÂurban India. European Respiratory Journal, 2019, 53, 1801563.	3.1	27

#	Article	IF	Citations
91	Diagnosis of idiopathic pulmonary fibrosis by virtual means using â€œIPFdatabaseâ€• a new software. Respiratory Medicine, 2019, 147, 31-36.	1.3	4
92	Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. European Respiratory Journal, 2019, 53, 1801655.	3.1	22
93	Response to Letter to Editor regarding "Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?". Respiratory Medicine, 2019, 149, 43-44.	1.3	1
94	Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors. European Respiratory Journal, 2019, 53, 1801699.	3.1	35
95	Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study. BMJ Open Respiratory Research, 2019, 6, e000443.	1.2	17
96	Hypersensitivity pneumonitis: Clinical manifestations â€“ Prospective data from the interstitial lung disease-India registry. Lung India, 2019, 36, 476.	0.3	7
97	Progress in the management of IPF-related acute exacerbations: a goal for patients, respirologists and intensivists. European Respiratory Journal, 2018, 51, 1800113.	3.1	1
98	Invasive Hemodynamics and Rejection Rates in Patients With Cardiac Sarcoidosis After Heart Transplantation. Canadian Journal of Cardiology, 2018, 34, 978-982.	0.8	20
99	Lung transplantation in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2018, 12, 375-385.	1.0	52
100	Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?. Lancet Respiratory Medicine,the, 2018, 6, 154-160.	5.2	137
101	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest, 2018, 153, 94-104.	0.4	66
102	2018 Clinical Practice Guideline Summary For Practicing Clinicians: Diagnosis of Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2018, 16, 285-290.	1.5	20
103	Palliative care for patients with pulmonary fibrosis: symptom relief is essential. European Respiratory Journal, 2018, 52, 1802086.	3.1	10
104	Idiopathic Pulmonary Fibrosis. Chest, 2018, 154, 1359-1370.	0.4	44
105	Cardiac sarcoidosis: Diagnosis confirmation by bronchoalveolar lavage and lung biopsy. Respiratory Medicine, 2018, 144, S13-S19.	1.3	20
106	SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). European Respiratory Journal, 2018, 52, 1801130.	3.1	59
107	Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2018, 379, 1722-1731.	13.9	207
108	Diagnosing idiopathic pulmonary fibrosis in 2018: bridging recommendations made by experts serving different societies. European Respiratory Journal, 2018, 52, 1801485.	3.1	23

#	Article	IF	Citations
109	Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?. Respiratory Medicine, 2018, 144, S20-S27.	1.3	38
110	Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSISÂ® trials. Respiratory Research, 2018, 19, 167.	1.4	42
111	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e44-e68.	2.5	2,678
112	Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA. European Respiratory Journal, 2018, 52, 1702106.	3.1	28
113	Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis. JAMA - Journal of the American Medical Association, 2018, 319, 2299.	3.8	170
114	Gastro-oesophageal reflux and idiopathic pulmonary fibrosis: the heart burn in patients with IPF can no longer be silent. European Respiratory Journal, 2018, 51, 1800921.	3.1	16
115	Identification of usual interstitial pneumonia pattern using RNA-Seq and machine learning: challenges and solutions. BMC Genomics, 2018, 19, 101.	1.2	23
116	Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 52, 1801384.	3.1	66
117	Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respiratory Medicine,the, 2018, 6, 707-714.	5.2	109
118	Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis. Respiratory Medicine, 2018, 140, 108-114.	1.3	11
119	Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis. , 2018, , 195-204.		0
120	Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 78-85.	2.5	147
121	Should we be concerned about air quality as a contributor to poor outcomes in lung transplant recipients?. European Respiratory Journal, 2017, 49, 1602369.	3.1	6
122	Pulmonary arteriovenous malformations: an uncharacterised phenotype of dyskeratosis congenita and related telomere biology disorders. European Respiratory Journal, 2017, 49, 1601640.	3.1	41
123	Epidemiology, survival, incidence and prevalence of idiopathic pulmonary fibrosis in the USA and Canada. European Respiratory Journal, 2017, 49, 1602384.	3.1	12
124	Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study. Thorax, 2017, 72, 472-474.	2.7	29
125	Reply: â€œThe ILD-India Registry: Ignoratio Elenchiâ€•and â€œThe ILD-India Registry: Look Before You Leapâ€• American Journal of Respiratory and Critical Care Medicine, 2017, 195, 837-839.	2.5	5
126	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1249-1254.	2.5	166

#	Article	IF	Citations
127	Pleuroparenchymal fibroelastosis associated with telomerase reverse transcriptase mutations. European Respiratory Journal, 2017, 49, 1700696.	3.1	8
128	High-Attenuation Areas on Chest Computed Tomography and Clinical Respiratory Outcomes in Community-Dwelling Adults. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1434-1442.	2.5	58
129	Antacid use and subclinical interstitial lung disease: the MESA study. European Respiratory Journal, 2017, 49, 1602566.	3.1	5
130	Current approaches to the management of idiopathic pulmonary fibrosis. Respiratory Medicine, 2017, 129, 24-30.	1.3	52
131	Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 680-689.	2.5	338
132	Idiopathic Interstitial Pneumonia Associated With Autoantibodies. Chest, 2017, 152, 103-112.	0.4	45
133	Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging. International Journal of Cardiology, 2017, 241, 457-462.	0.8	41
134	The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. Lancet Respiratory Medicine,the, 2017, 5, 61-71.	5.2	79
135	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 22-32.	5.2	200
136	N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open. Lancet Respiratory Medicine,the, 2017, 5, e1-e2.	5.2	13
137	Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25â€…years. European Respiratory Journal, 2017, 50, 1701209.	3.1	108
138	Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. European Respiratory Review, 2017, 26, 170071.	3.0	30
139	Idiopathic pulmonary fibrosis. Nature Reviews Disease Primers, 2017, 3, 17074.	18.1	786
140	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	3.1	75
141	Occupational Exposures and Subclinical Interstitial Lung Disease. The MESA (Multi-Ethnic Study of) Tj ETQq1 1 0.784314 rgBT /Overlock 2017, 196, 1031-1039.	2.5	46
142	Air pollution and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA) airâ€“lung study. European Respiratory Journal, 2017, 50, 1700559.	3.1	86
143	Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning. Annals of the American Thoracic Society, 2017, 14, 1646-1654.	1.5	77
144	Interstitial Lung Disease in India. Results of a Prospective Registry. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 801-813.	2.5	170

#	Article	IF	Citations
145	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. Journal of Rheumatology, 2016, 43, 1672-1679.	1.0	222
146	First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity ofÂâ‰50Â% of Predicted Value. Lung, 2016, 194, 739-743.	1.4	102
147	Rheumatoid arthritis-associated autoantibodies and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. Thorax, 2016, 71, 1082-1090.	2.7	59
148	Interstitial pneumonia with autoimmune features: the new consensus-based definition for this cohort of patients should be broadened. European Respiratory Journal, 2016, 47, 1293-1295.	3.1	26
149	Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18â€“64â€…years old. European Respiratory Journal, 2016, 48, 179-186.	3.1	218
150	Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications. Expert Review of Respiratory Medicine, 2016, 10, 699-711.	1.0	10
151	Idiopathic Pulmonary Fibrosis: Novel Concepts of Proton Pump Inhibitors as Antifibrotic Drugs. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1345-1352.	2.5	71
152	Idiopathic pulmonary fibrosis: combating on a new turf. Lancet Respiratory Medicine,the, 2016, 4, 430-432.	5.2	6
153	Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre. European Respiratory Journal, 2016, 48, 826-832.	3.1	47
154	High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. European Respiratory Journal, 2016, 48, 1442-1452.	3.1	110
155	Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. European Respiratory Journal, 2016, 48, 1710-1720.	3.1	281
156	Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution. Lancet Respiratory Medicine,the, 2016, 4, e46-e47.	5.2	6
157	Idiopathic pulmonary fibrosis â€“ clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?. BMC Medicine, 2016, 14, 22.	2.3	7
158	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275.	2.5	1,006
159	Symptomatic Respiratory Virus Infection and Chronic Lung Allograft Dysfunction. Clinical Infectious Diseases, 2016, 62, 313-319.	2.9	92
160	Drug Treatment of Idiopathic Pulmonary Fibrosis. Chest, 2016, 149, 756-766.	0.4	155
161	Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Medicine, 2016, 14, 18.	2.3	79
162	Persistent breathlessness. Lancet, The, 2016, 387, e21.	6.3	1

#	Article	IF	Citations
163	FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. European Respiratory Journal, 2016, 47, 1481-1491.	3.1	147
164	Treatment of Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2016, 13, 115-117.	1.5	19
165	Interstitial lung disease (ILD) in India: Insights and lessons from the prospective, landmark ILD-India registry. Lung India, 2016, 33, 589.	0.3	15
166	Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. Journal of Translational Medicine, 2015, 13, 249.	1.8	105
167	Development of Novel Agents for Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, 1083-1092.	0.4	22
168	Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respiratory Medicine,the, 2015, 3, 473-482.	5.2	112
169	Nintedanib and Pirfenidone. New Antifibrotic Treatments Indicated for Idiopathic Pulmonary Fibrosis Offer Hopes and Raises Questions. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 252-254.	2.5	135
170	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2015, 192, e3-e19.	2.5	1,521
171	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respiratory Medicine,the, 2015, 3, 388-396.	5.2	69
172	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. European Respiratory Journal, 2015, 46, 243-249.	3.1	48
173	Rheumatoid arthritis-associated lung disease. European Respiratory Review, 2015, 24, 1-16.	3.0	220
174	CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. European Respiratory Journal, 2015, 46, 1740-1750.	3.1	97
175	The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF. European Respiratory Journal, 2015, 46, 883-886.	3.1	18
176	Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. European Respiratory Journal, 2015, 46, 1113-1130.	3.1	328
177	Idiopathic pulmonary fibrosis: tracking the true occurrence is challenging. European Respiratory Journal, 2015, 46, 604-606.	3.1	25
178	Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. European Respiratory Journal, 2015, 46, 1370-1377.	3.1	129
179	TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1475-1482.	2.5	257
180	Health Care Utilization and Costs of Idiopathic Pulmonary Fibrosis in U.S. Medicare Beneficiaries Aged 65 Years and Older. Annals of the American Thoracic Society, 2015, 12, 981-987.	1.5	85

#	Article	IF	Citations
181	An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. European Respiratory Journal, 2014, 44, 1479-1503.	3.1	442
182	Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. European Respiratory Journal, 2014, 44, 1296-1307.	3.1	177
183	A new classification system for chronic lung allograft dysfunction. Journal of Heart and Lung Transplantation, 2014, 33, 127-133.	0.3	454
184	Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2093-2101.	13.9	422
185	Smoking-related idiopathic interstitial pneumonia. European Respiratory Journal, 2014, 44, 594-602.	3.1	36
186	Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT â€“ Authors' reply. Lancet Respiratory Medicine,the, 2014, 2, e5-e6.	5.2	1
187	Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2071-2082.	13.9	3,351
188	Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001â€“11. Lancet Respiratory Medicine,the, 2014, 2, 566-572.	5.2	513
189	Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 277-284.	5.2	162
190	Study Design Implications of Death and Hospitalization as End Points in Idiopathic Pulmonary Fibrosis. Chest, 2014, 146, 1256-1262.	0.4	28
191	Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respiratory Medicine,the, 2013, 1, 685-694.	5.2	308
192	An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 733-748.	2.5	3,134
193	Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. European Respiratory Journal, 2013, 42, 1622-1632.	3.1	227
194	Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respiratory Medicine,the, 2013, 1, 369-376.	5.2	349
195	Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan. Annals of Internal Medicine, 2013, 158, 641.	2.0	437
196	An Official American Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1004-1014.	2.5	832
197	Idiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012. Lancet, The, 2012, 380, 699-701.	6.3	17
198	Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1044-1048.	2.5	209

#	Article	IF	Citations
199	Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary Fibrosis. New England Journal of Medicine, 2012, 366, 1968-1977.	13.9	1,353
200	Rheumatoid Arthritisâ€“Interstitial Lung Diseaseâ€“associated Mortality. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 372-378.	2.5	389
201	An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 788-824.	2.5	6,033
202	Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2011, 365, 1079-1087.	13.9	930
203	Idiopathic Pulmonary Fibrosis: Increased Survival with â€œGastroesophageal Reflux Therapyâ€• American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1330-1332.	2.5	45
204	Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 459-466.	2.5	367
205	Polymyositis Associated With Severe Interstitial Lung Disease. Chest, 2011, 139, 441-443.	0.4	74
206	BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 92-99.	2.5	497
207	The SF-36 and SGRQ: Validity and first look at minimum important differences in IPF. Respiratory Medicine, 2010, 104, 296-304.	1.3	210
208	Does Chronic Microaspiration Cause Idiopathic Pulmonary Fibrosis?. American Journal of Medicine, 2010, 123, 304-311.	0.6	183
209	Seasonal Variation. Chest, 2009, 136, 16-22.	0.4	37
210	Improving the Standard of Care for Patients With Idiopathic Pulmonary Fibrosis Requires Participation in Clinical Trials. Chest, 2009, 136, 330-333.	0.4	17
211	BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 75-81.	2.5	487
212	Treatment of Idiopathic Pulmonary Fibrosis with Etanercept. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 948-955.	2.5	338
213	Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 729-737.	2.5	481
214	Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1054-1060.	2.5	241
215	Acute Exacerbations of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 636-643.	2.5	996
216	Sole Treatment of Acid Gastroesophageal Reflux in Idiopathic Pulmonary Fibrosis. Chest, 2006, 129, 794-800.	0.4	206

#	Article	IF	Citations
217	Incidence and Prevalence of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 810-816.	2.5	1,113
218	High-Resolution Computed Tomography in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 488-493.	2.5	470
219	Analyses of Efficacy End Points in a Controlled Trial of Interferon-Î³1b for Idiopathic Pulmonary Fibrosis. Chest, 2005, 127, 171-177.	0.4	215
220	The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis. Annals of Internal Medicine, 2005, 142, 963.	2.0	530
221	Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 904-910.	2.5	574
222	A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2004, 350, 125-133.	13.9	649
223	Interstitial lung disease: clinical evaluation and keys to an accurate diagnosis. Clinics in Chest Medicine, 2004, 25, 409-419.	0.8	58
224	Idiopathic pulmonary fibrosis: current trends in management. Clinics in Chest Medicine, 2004, 25, 621-636.	0.8	28
225	The role of gastroesophageal reflux in idiopathic pulmonary fibrosis. American Journal of Medicine, 2003, 115, 60-64.	0.6	65
226	Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 1061-1069.	2.5	445
227	Assessment of Health-Related Quality of Life in Patients With Interstitial Lung Disease. Chest, 1999, 116, 1175-1182.	0.4	252
228	The Accuracy of the Clinical Diagnosis of New-Onset Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Disease. Chest, 1999, 116, 1168-1174.	0.4	380
229	Increased Prevalence of Gastroesophageal Reflux in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1804-1808.	2.5	513
230	Elevated Transforming Growth Factor-Î± Levels in Bronchoalveolar Lavage Fluid of Patients with Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 424-430.	2.5	121
231	Interstitial Lung Disease: A Diagnostic Approach: Are CT Scan and Lung Biopsy Indicated in Every Patient?. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 909-914.	2.5	116
232	Human Lung Fibroblast Subpopulations with Different C1q Binding and Functional Properties. American Journal of Respiratory Cell and Molecular Biology, 1992, 6, 382-389.	1.4	24
233	Pneumocystis carinii pneumonia associated with profound lymphopenia and abnormal T-lymphocyte subset ratios during treatment for early-stage breast carcinoma. Cancer, 1991, 67, 2407-2409.	2.0	30
234	Azathioprine Combined with Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: A Prospective Double-blind, Randomized, Placebo-controlled Clinical Trial. The American Review of Respiratory Disease, 1991, 144, 291-296.	2.9	394

#	Article	IF	Citations
235	Differential Proliferation of Fibroblasts Cultured from Normal and Fibrotic Human Lungs. The American Review of Respiratory Disease, 1988, 138, 703-708.	2.9	143
236	Reply to: Idiopathic Pulmonary Fibrosis Update. Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	0
237	Genome-wide Enrichment of TERT Rare Variants in IPF Patients of Latino Ancestry. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	6